Corinna Kulicke

7PUBLICATIONS
44CO-AUTHORS
Medical mycologyTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 02, 2026
An MR1-specific nanobody capable of blocking MR1T cell activation.

|Apr 14, 2026
Synaptotagmin 1 and Synaptotagmin 7 promote MR1-mediated presentation of Mycobacterium tuberculosis antigens.

Se-Jin Kim, Jessie C Peterson, Andrew J Olive

|Jun 06, 2025
Mutations outside the MR1 antigen binding groove differentially inhibit presentation of exogenous antigens.

Corinna A Kulicke, Chance Lemon, Jason R Krawic

|Apr 24, 2024
Publisher Correction: Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Mike B Barnkob, Yale S Michaels, Violaine André

|Apr 12, 2024
Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Mike B Barnkob, Yale S Michaels, Violaine André

|Feb 24, 2024
Delivery of loaded MR1 monomer results in efficient ligand exchange to host MR1 and subsequent MR1T cell activation.

Corinna A Kulicke, Gwendolyn M Swarbrick, Nicole A Ladd

Pageof 2

Frequent Collaborators

4 joint publications

David M Lewinsohn

4 joint publications

Fikadu G Tafesse

3 joint publications

Jason R Krawic

2 joint publications

Yale S Michaels